Dr. Reddy's Laboratories Ltd. News and Updates

Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 1
Author: Deven Choksey

Keep track of all breaking news on Dr. Reddy's Laboratories Ltd. from all sources in a single place.

Dr. Reddy's Laboratories Ltd.

10 Nov 2025

1246.00

0.90%

Dr Reddy's Labs loses 2.16 cr after email fraud by cyber criminals

Business Standard

The Bengaluru police have launched a probe into a cyber fraud case where hackers allegedly infiltrated the official email communication between city-based Group Pharmaceuticals and Dr Reddy's Laboratories, Hyderabad, successfully diverting a payment of Rs 2.16 crore to a fraudulent account. According to an FIR registered by the Cyber Crime Police Station, Bengaluru City, the fraud was reported by Mahesh Babu K, a senior executive with Group Pharmaceuticals. The company stated it was expecting a payment of Rs 2.16 crore from Dr. Reddy's Laboratories for goods supplied. During the course of their business, they had supplied goods to Dr Reddy's Laboratories, and were due to receive a payment of Rs 2.16 crore, the FIR stated. However, on November 3, hackers allegedly gained unauthorised access to the email communication between the two companies and sent fraudulent emails to Dr Reddy's finance and accounts team, impersonating officials of Group Pharmaceuticals and providing false bank .

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Cyber fraudstersdupe' Dr Reddy's of 2 crore by hacking email communication

Business Line | 09 Nov 2025 1 more

Dr. Reddy's Laboratories Ltd.

06 Nov 2025

1246.00

0.90%

Dr Reddy's to leverage its products in US, Europe for growth in India, emerging markets

Business Line

With a hefty revenue of $3.8 billion in FY25, this Indian giant is making waves in 45 countries, from Asia to Africa and beyond. CEO MV Ramana shared that the focus is on exciting branded generics and innovative launches, like Tegoprazan and Linaclotide, to connect with consumers

Dr. Reddy's Laboratories Ltd. is trading below its 50 day SMA of 1259.2

Dr. Reddy's Laboratories Ltd.

30 Oct 2025

1246.00

0.90%

Canada notice delays Dr Reddy's semaglutide generic by up to a year

Business Standard

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday

Dr. Reddy's Laboratories Ltd. is trading below its 50 day SMA of 1259.2

Dr Reddy's shares down as weight-loss drug faces regulatory setback in Canada

Business Line | 30 Oct 2025 2 more

Dr. Reddy's Laboratories Ltd.

29 Oct 2025

1246.00

0.90%

A muted quarter as robust growth across non-US markets was offset by US pricing pressure.

Sell: Dr. Reddy's Laboratories Ltd.

Target

Deven Choksey

Although the company continues to strengthen its presence through new launches, portfolio expansion, and biosimilar development, persistent pricing pressure in the U.S. generics business and adverse product mix are expected to remain key headwinds to its overall profitability.

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1246.00

0.90%

New launch traction for Dr Reddy's key to offsetting price erosion

Business Standard

Given that price erosion in the North American market is expected to continue in the near term, some brokerages have cut their earnings estimates for the stock

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1230.8

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1246.00

0.90%

Dr. Reddy's Q2 Review Systematix Maintains 'Hold' Post Inline Results; Strong Performance In Ex -US Markets

NDTV Profit

Except North America which declined 13% YoY, Dr. Reddy's other business segments showed strong growth, adds the brokerage.

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1230.8

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1246.00

0.90%

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Business Standard

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of 1,437.2 crore, up 14 per cent Y-o-Y from 1,255.3 crore, with sequential growth largely flat.

Dr. Reddy's Laboratories Ltd. is trading below its 50 day SMA of 1259.2

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1246.00

0.90%

Result Update:Dr Reddys Labs

Hold: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

We maintain our HOLD recommendation on the stock.

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1246.00

0.90%